BioCentury
ARTICLE | Clinical News

Humira adalimumab regulatory update

October 29, 2012 7:00 AM UTC

EMA's CHMP issued a positive opinion to expand the label of Abbott's Humira adalimumab to include treatment of patients aged 6-17 years with severely active Crohn's disease who failed, are intolerant ...